Orchard Therapeutics Strongly Supports Enactment Of Newborn Metabolic Screening Act In Illinois, Adding Metachromatic Leukodystrophy To Statewide Panel
Portfolio Pulse from Happy Mohamed
Orchard Therapeutics (NASDAQ:ORTX) has expressed support for the Newborn Metabolic Screening Act in Illinois, which mandates the expansion of the state's Newborn Screening program to include metachromatic leukodystrophy (MLD) from January 2024. Illinois is the first US state to add newborn screening for MLD. Orchard Therapeutics is supporting several newborn screening initiatives, including nine prospective newborn screening studies across Europe, the US, and the Middle East.
August 04, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Orchard Therapeutics' support for the Newborn Metabolic Screening Act in Illinois could potentially increase the company's visibility and reputation in the healthcare sector.
Orchard Therapeutics' support for the Newborn Metabolic Screening Act in Illinois, which includes MLD in newborn screening, aligns with the company's mission and could potentially enhance its reputation in the healthcare sector. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100